Icon has today announced a deal to buy US-based PriceSpective, a global leader in value strategy consulting.
The company said the acquisiton will strengthen its expertise in value based pricing and market access. It said along with a recent deal to buy Oxford Outcomes, ICON will now be able to offer the industry's most integrated regulatory, clinical and market access solution.
Icon, which provides services to the pharmaceutical, biotechnology and medical device industries, did not disclose the price it paid for PriceSpective.
PriceSpective is headquartered in Philadelphia in the US and has offices in London, Los Angeles, San Diego, Raleigh and Boston.
''PriceSpective's strategic expertise, coupled with its strong network of relationships with thousands of payers and market experts worldwide, makes it the perfect addition to our service portfolio," commented Icon's CEO Ciaran Murray
